Claims for Patent: 10,624,850

Summary for Patent: 10,624,850

Title:	Emulsion formulations of an NK-1 receptor antagonist and uses thereof
Abstract:	Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration. Also included are formulations including both the NK-1 receptor antagonist and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.
Inventor(s):	Thomas B. Ottoboni, Han Han
Assignee:	Heron Therapeutics LLC
Application Number:	US15/965,638
Patent Claims:	1. A method for treating a subject, comprising administering to the subject an injectable pharmaceutical emulsion, wherein the emulsion comprises: a neurokinase-1 (NK-1) receptor antagonist; 11 wt/wt % to 15 wt/wt % of an emulsifier; an oil; a co-surfactant which comprises an alcohol; a tonicity agent; a pH modifier; and water; wherein the pH of the emulsion ranges from about 7.5 to 9.0, and the ratio of the emulsifier to the NK-1 receptor antagonist ranges from about 18:1 to 22:1 (wt/wt %), and wherein the subject is at risk of or is suffering from nausea and/or vomiting. 2. The method according to claim 1, wherein the ratio of the oil to the NK-1 receptor antagonist ranges from about 5:1 to 15:1 (wt/wt %). 3. The method according to claim 1, wherein the ratio of the oil to the NK-1 receptor antagonist ranges from about 10:1 to 15:1 (wt/wt %). 4. The method according to claim 1, wherein the ratio of emulsifier to oil ranges from about 1:1 to 3:1 (wt/wt %). 5. The method according to claim 1, wherein the emulsifier is a phospholipid. 6. The method according to claim 1, wherein the emulsifier is an egg lecithin. 7. The method according to claim 1, wherein the emulsion further comprises dexamethasone sodium phosphate, wherein the dexamethasone sodium phosphate is present in the aqueous phase. 8. The method according to claim 1, wherein the NK-1 receptor antagonist is selected from the group consisting of rolapitant, netupitant, ezlopitant, vestipitant, serlopitant, maropitant, casopitant, befetupitant, and orvepitant. 9. The method according to claim 1, wherein the pH modifier is oleic acid or a salt thereof. 10. The method according to claim 1, wherein the pH modifier is a buffer. 11. The method according to claim 10, wherein the buffer is Tris buffer. 12. The method according to claim 1, wherein the oil is soybean oil. 13. The method according to claim 1, wherein the alcohol is ethanol. 14. The method according to claim 13, wherein the ethanol is present in the emulsion at less than 10 wt/wt %. 15. The method according to claim 1, wherein the NK-1 receptor antagonist is not aprepitant. 16. The method according to claim 1, wherein the nausea and/or vomiting is induced by chemotherapy, surgery, or radiotherapy.